Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,685 Mln
P/E Ratio
11.7
P/B Ratio
2.56
Industry P/E
--
Debt to Equity
0.02
ROE
0.26 %
ROCE
21.78 %
Div. Yield
0 %
Book Value
11.36
EPS
2.51
CFO
$345.19 Mln
EBITDA
$269.14 Mln
Net Profit
$95.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Harmony Biosciences Holdings (HRMY)
| -14.44 | -11.30 | -23.37 | 0.41 | -13.77 | -- | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Harmony Biosciences Holdings (HRMY)
| 6.48 | -41.38 | 29.22 | 17.95 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.42 | 6,839.20 | -- | 38.11 | |
| 73.23 | 7,493.81 | 57.68 | 23.56 | |
| 60.43 | 11,518.55 | 396.8 | 0.76 | |
| 8.34 | 9,847.94 | -- | -3.24 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a... molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 Read more
Founder & Non-Executive Chairman
Mr. Jeffrey S. Aronin
Founder & Non-Executive Chairman
Mr. Jeffrey S. Aronin
Headquarters
Plymouth Meeting, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Harmony Biosciences Holdings (HRMY) stood at $ 999 Mln as on 31-Dec-24
The share price of Harmony Biosciences Holdings (HRMY) is $29.44 (NASDAQ) as of 29-Apr-2025 16:26 EDT. Harmony Biosciences Holdings (HRMY) has given a return of -13.77% in the last 3 years.
Harmony Biosciences Holdings (HRMY) has a market capitalisation of $ 1,685 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Harmony Biosciences Holdings (HRMY) is 11.70 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Harmony Biosciences Holdings (HRMY) and enter the required number of quantities and click on buy to purchase the shares of Harmony Biosciences Holdings (HRMY).
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
The CEO & director of Mr. Jeffrey S. Aronin. is Harmony Biosciences Holdings (HRMY), and CFO & Sr. VP is Mr. Jeffrey S. Aronin.
There is no promoter pledging in Harmony Biosciences Holdings (HRMY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Harmony Biosciences Holdings (HRMY) | Ratios |
|---|---|
|
Return on equity(%)
|
25.84
|
|
Operating margin(%)
|
29.28
|
|
Net Margin(%)
|
20.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Harmony Biosciences Holdings (HRMY) was $0 Mln.
$0.08
(
